Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
56 shown of 6,933 total abstracts
  1. Abstract 18732026-06-02 · 18:00 CT · Hall B1
    IMpower-583: Tecentriq (atezolizumab) 3L+ in TNBC
    T. Mok, S. Peters, M. Reck, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  2. Abstract 19552026-06-05 · 13:45 CT · E450
    OlympiA-356: Lynparza (olaparib) 1L in HR+ breast cancer
    G. Curigliano, J. Cortes · Royal Marsden Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  3. Abstract 18612026-06-01 · 21:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-824 study)
    C. Saura, F. Andre, H. Borghaei, et al. · Royal Marsden Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  4. Abstract 17822026-06-04 · 20:45 CT · S100A
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-759 study)
    J. Cortes, C. Robert, F. Andre · Cleveland Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  5. Abstract 15182026-06-04 · 20:30 CT · E450
    Long-term follow-up of Enhertu neoadjuvant for HR+ breast cancer: DESTINY-Breast-563
    M.C. Garassino, A. Spira, R. Herbst, et al. · Institut Gustave Roussy
    Education SessionBreast Cancer—Metastatic📄🖼️
  6. Abstract 14302026-06-02 · 13:30 CT · Hall B1
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    M. Krop, S. Modi, S. Antonia, et al. · Princess Margaret Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  7. Abstract 11522026-06-01 · 18:15 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-928 study)
    S. Modi, C. Robert, R. Herbst, et al. · Institut Gustave Roussy
    Education SessionBreast Cancer—Metastatic📄🖼️
  8. Abstract 14252026-06-05 · 15:45 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-727
    R. Herbst, M.C. Garassino, S. Antonia, et al. · Dana-Farber Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  9. Abstract 13602026-06-05 · 20:30 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-534
    C. Robert, F. Andre, R. Herbst, et al. · Chinese University of Hong Kong
    Education SessionBreast Cancer—Metastatic📄🖼️
  10. Abstract 12672026-06-04 · 13:00 CT · E450
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    M.C. Garassino, P. Schmid · Dana-Farber Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  11. Abstract 15572026-06-02 · 15:00 CT · E450
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    S. Antonia, C. Robert, J. Brahmer, et al. · Royal Marsden Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  12. Abstract 12092026-06-02 · 20:00 CT · Hall B1
    IMpower-709: Tecentriq (atezolizumab) 3L+ in TNBC
    T. Mok, N. Rizvi, S. Peters, et al. · Mayo Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  13. Abstract 16132026-06-04 · 19:00 CT · Arie Crown Theater
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    S. Antonia, M. Krop, M. Reck · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  14. Abstract 15152026-06-03 · 15:30 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-788
    E. Winer, N. Rizvi · Chinese University of Hong Kong
    Education SessionBreast Cancer—Metastatic📄🖼️
  15. Abstract 14772026-06-03 · 19:45 CT · E450
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-667
    G. Curigliano, L. Paz-Ares, M. Reck · Dana-Farber Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  16. Abstract 16592026-06-05 · 13:30 CT · S100A
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-756 study)
    S. Modi, C. Robert, S. Tolaney, et al. · Cleveland Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  17. Abstract 19602026-06-05 · 18:45 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-893
    P. Schmid, G. Curigliano, F. Andre, et al. · National Cancer Center Japan
    Education SessionBreast Cancer—Metastatic📄🖼️
  18. Abstract 17292026-06-03 · 14:15 CT · E450
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-577
    S. Peters, T. Mok, R. Herbst, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  19. Abstract 11372026-06-05 · 13:00 CT · E450
    ASCENT-956: Trodelvy (sacituzumab govitecan) neoadjuvant in TNBC
    C. Robert, M.C. Garassino, N. Rizvi · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  20. Abstract 18412026-06-03 · 20:30 CT · Hall B1
    MONARCH-489: Verzenio (abemaciclib) 1L in HR+ breast cancer
    S. Modi, C. Robert · Karolinska Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  21. Abstract 11642026-06-05 · 18:15 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-281 study)
    S. Tolaney, H. Borghaei, M. Reck, et al. · Vall d'Hebron Institute of Oncology
    Education SessionBreast Cancer—Metastatic📄🖼️
  22. Abstract 17162026-06-01 · 16:00 CT · E450
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-415
    R. Herbst, C. Saura, M. Krop · Johns Hopkins Kimmel Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  23. Abstract 17952026-06-03 · 16:30 CT · Hall B1
    Long-term follow-up of Enhertu neoadjuvant for HR+ breast cancer: DESTINY-Breast-288
    A. Spira, S. Antonia, R. Herbst · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  24. Abstract 19082026-06-04 · 21:15 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-299 study)
    M.C. Garassino, E. Winer, C. Saura · Royal Marsden Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  25. Abstract 10122026-06-03 · 13:15 CT · Arie Crown Theater
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    H. Borghaei, T. Mok, L. Paz-Ares, et al. · National Cancer Center Japan
    Education SessionBreast Cancer—Metastatic📄🖼️
  26. Abstract 15652026-06-01 · 21:15 CT · Arie Crown Theater
    MONARCH-875: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    S. Antonia, M.C. Garassino, P. Schmid · Princess Margaret Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  27. Abstract 15512026-06-04 · 15:15 CT · Hall B1
    Quality of life outcomes with Trodelvy in patients with TNBC
    M.C. Garassino, S. Antonia, C. Saura, et al. · Karolinska Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  28. Abstract 17482026-06-03 · 21:15 CT · S406
    Long-term follow-up of Verzenio 1L for HR+ breast cancer: MONARCH-766
    S. Modi, P. Schmid, E. Winer, et al. · Cleveland Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  29. Abstract 14532026-06-03 · 13:00 CT · S406
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-525
    F. Andre, G. Curigliano, A. Spira · University of Chicago
    Education SessionBreast Cancer—Metastatic📄🖼️
  30. Abstract 16662026-06-01 · 21:45 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-230
    J. Cortes, M. Krop, T. Mok · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  31. Abstract 14262026-06-04 · 15:15 CT · Hall B1
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-740
    M. Krop, N. Rizvi, G. Curigliano · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  32. Abstract 12632026-06-04 · 21:00 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-655 study)
    J. Cortes, M. Krop · Chinese University of Hong Kong
    Education SessionBreast Cancer—Metastatic📄🖼️
  33. Abstract 19282026-06-02 · 21:00 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-538
    H. Borghaei, A. Spira · Stanford Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  34. Abstract 11912026-06-05 · 16:45 CT · Arie Crown Theater
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    S. Modi, F. Andre, J. Cortes, et al. · Cleveland Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  35. Abstract 10982026-06-05 · 18:00 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-809 study)
    T. Mok, A. Spira, M. Krop, et al. · Royal Marsden Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  36. Abstract 16302026-06-03 · 16:45 CT · S100A
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-874
    F. Andre, H. Borghaei, G. Curigliano · National Cancer Center Japan
    Education SessionBreast Cancer—Metastatic📄🖼️
  37. Abstract 18382026-06-02 · 21:45 CT · Hall B1
    ASCENT-945: Trodelvy (sacituzumab govitecan) 3L+ in TNBC
    C. Saura, G. Curigliano, N. Rizvi, et al. · Princess Margaret Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  38. Abstract 18552026-06-02 · 19:15 CT · S406
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-887
    T. Mok, H. Rugo, H. Borghaei, et al. · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  39. Abstract 16122026-06-02 · 15:30 CT · S406
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    P. Schmid, S. Peters, M.C. Garassino, et al. · Dana-Farber Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  40. Abstract 13682026-06-02 · 20:45 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-76
    M. Reck, S. Antonia, M. Krop, et al. · Cleveland Clinic
    Education SessionBreast Cancer—Metastatic📄🖼️
  41. Abstract 19632026-06-02 · 16:15 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-422 study)
    P. Schmid, C. Robert, J. Brahmer, et al. · Royal Marsden Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  42. Abstract 10422026-06-05 · 19:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-893 study)
    R. Herbst, S. Antonia, M. Reck, et al. · Chinese University of Hong Kong
    Education SessionBreast Cancer—Metastatic📄🖼️
  43. Abstract 12622026-06-01 · 14:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-533 study)
    T. Mok, R. Herbst, M. Reck, et al. · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  44. Abstract 10362026-06-03 · 20:00 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-569 study)
    N. Rizvi, M.C. Garassino, J. Cortes, et al. · Memorial Sloan Kettering Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  45. Abstract 12132026-06-02 · 21:00 CT · S406
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    S. Modi, M.C. Garassino, A. Spira, et al. · Chinese University of Hong Kong
    Education SessionBreast Cancer—Metastatic📄🖼️
  46. Abstract 19352026-06-01 · 21:15 CT · S100A
    MONALEESA-736: Kisqali (ribociclib) 2L in HR+ breast cancer
    C. Robert, M. Krop, M.C. Garassino, et al. · Massachusetts General Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  47. Abstract 11692026-06-01 · 20:15 CT · E450
    Long-term follow-up of Verzenio adjuvant for HR+ breast cancer: MONARCH-871
    S. Peters, M. Krop · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  48. Abstract 17892026-06-05 · 20:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-381 study)
    P. Schmid, S. Modi, J. Cortes, et al. · Memorial Sloan Kettering Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  49. Abstract 19372026-06-04 · 14:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-946 study)
    S. Antonia, A. Spira, M.C. Garassino, et al. · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  50. Abstract 18992026-06-03 · 16:45 CT · Hall B1
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-865
    R. Herbst, L. Paz-Ares, S. Peters, et al. · Karolinska Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  51. Abstract 11002026-06-02 · 13:30 CT · S100A
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    R. Herbst, C. Robert, H. Borghaei · National Cancer Center Japan
    Education SessionBreast Cancer—Metastatic📄🖼️
  52. Abstract 12312026-06-02 · 20:45 CT · Hall B1
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-168 study)
    H. Rugo, F. Andre · Dana-Farber Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  53. Abstract 17042026-06-01 · 13:15 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-598 study)
    G. Curigliano, H. Borghaei, J. Brahmer, et al. · Massachusetts General Hospital
    Education SessionBreast Cancer—Metastatic📄🖼️
  54. Abstract 17372026-06-02 · 14:45 CT · S100A
    Long-term follow-up of Tecentriq 2L for TNBC: IMpower-334
    J. Brahmer, H. Rugo, N. Rizvi · Peter MacCallum Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  55. Abstract 12992026-06-05 · 20:45 CT · S406
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-381
    T. Mok, S. Antonia, S. Peters, et al. · Chinese University of Hong Kong
    Education SessionBreast Cancer—Metastatic📄🖼️
  56. Abstract 13152026-06-03 · 19:00 CT · S406
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-2 study)
    J. Brahmer, N. Rizvi · Dana-Farber Cancer Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.